Clay Seigall; Trying to Change the Lives of Cancer Patients

On, Clay Seigall posts about the news happening today. Lately it has been about the Paris Climate Agreement and how President Trump announced that the United States would be withdrawing from it. He has also posted about an Electric CEO and a key Republican governor who have been critical of the President in not being a part of the Paris Agreement, as the President is going backwards when it comes to clean energy and jobs.

One of his posts deals with the fallout from Kathy Griffin’s photo of her with a severed head of Trump, and some have been quick to criticize the comedienne for that, while forgetting it wasn’t that long ago people were hanging up effigies of Obama while he was in office. More of Clay’s posts deal with health, technology, and advances in predicting hurricanes better and the latest with NASA.

Clay Seigall attended the University of Maryland where he earned his Bachelor of Science degree in Zoology, and The George Washington University and earned his Ph.D. in Philosophy and Genetics. He became a part of the National Cancer Institute, National Institutes of Health and was there from 1988 to 1991. From there, Clay was at Bristol-Meyers Squibb Pharmaceutical Research Institute from 1991 to 1997. Clay Seigall in 1998 co-founded Seattle Genetics and is the President, Chief Executive Officer, and a member of the board of directors. The company’s goal is to advance a variety of portfolios of preclinical and clinical product suitable patients aiming at different autoimmune indications and cancer. In addition, the company is leading in antibody technologies, specifically ADC (anti-body drug conjugate) platform.

Dr. Seigall is very passionate in regards to making the lives of cancer patients better. He is committed to research and using only the best research developments. Due to Dr. Seigall’s dedication and drive, Seattle Genetics created the very first ADC, which includes ADCETRIS® which received FDA approval in 2011. This drug is now available in over 60 countries, helping many cancer patients. Dr. Seigall has been the leader in getting funds of over $1.2 billion dollars in private and public funding for Seattle Genetics. He hasn’t slowed down one bit, as he currently holds 15 patents, and pushes for more research. With Dr. Seigall’s leadership skills, ability to raise money, and his commitment to cancer patients, he may be able to find the cure for cancer.